2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
23/06/26	SEK 1.880	-5.81%	23,945
22/06/26	SEK 1.996	+4.50%	81,750
18/06/26	SEK 1.910	-4.98%	35,531
17/06/26	SEK 2.010	+22.56%	222,072
16/06/26	SEK 1.640	-4.98%	15,730

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Stockholm Other stock markets 20:00:00 23/06/2026 +04			5-day change	1st Jan Change
1.880 ^SEK	-5.81%		+8.92%	+265.76%

05-26	2cureX AB Proposes No Dividend for the Financial Year 2025	CI
05-26	2Curex AB Announces Tonni Bülow-Nielsen Declines Re-Election as Director	CI

Market Cap	7.43M 764K 671K 619K 579K 1.09M 72.4M 1.1M 2.88M 35.52M 2.87M 2.81M 123M	P/E 2022	-4.81x	P/E 2023	-1.09x
Enterprise Value	-5.97M -615K -540K -498K -466K -873K -58.23M -887K -2.31M -28.57M -2.31M -2.26M -99.3M	EV / Sales 2022	29.3x	EV / Sales 2023	7.46x
Free-Float	34.89%	Yield 2022 *	-	Yield 2023	-

05-26	2cureX AB Proposes No Dividend for the Financial Year 2025	CI
05-26	2Curex AB Announces Tonni Bülow-Nielsen Declines Re-Election as Director	CI
05-20	2cureX AB - Shareholder/Analyst Call
05-20	2cureX signs collaboration deal with StoreMyTumor	RE
05-20	2cureX AB and StoreMyTumor Sign Strategic Collaboration Agreement	CI
04-22	2cureX Raises SEK7.5 Million Through Directed Share Issue	MT
04-22	2cureX raises about SEK 7.51 mln through share issue	RE
02-27	2cureX H2 operating loss at SEK 644,000	RE
21/08/25	2cureX AB (OM:2CUREX) acquired Cellphenomics GmbH for ?44 million.	CI
06/07/25	2cureX AB - Special Call
16/06/25	2cureX AB Announces Annual dividend, payable on July 03, 2025	CI
20/05/25	2cureX Conducts First Direct-To-Patient IndiTreat®? Test Under "Operation Twin Code" Strategy	CI
16/05/25	2cureX CEO To Step Down	RE

05-28	THIS PRESS RELEASE IS AN ENGLISH TRANSLATION OF THE LEGALLY BINDING SWEDISH PRESS RELEASE: “PUBLICERING AV ÅRSREDOVISNINGEN FÖR 2CUREX AB (publ)”.	AQ
05-25	Notice of annual general meeting in 2cureX AB	AQ
05-20	2cureX AB Expands Functional Precision Medicine Infrastructure Through Strategic Collaboration with StoreMyTumor	AQ
05-19	2cureX AB’s Executive Management is pleased to invite shareholders and investors to a live webcast and business update on 20 May at 7pm CET.	AQ
04-22	2cureX AB completes oversubscribed directed issue	AQ

2cureX AB Stock

Stocks

2CUREX

SE0010468124

Biotechnology & Medical Research

Valuation: 2cureX AB

Chart: 2cureX AB

Latest news : 2cureX AB

Last Transcript: 2cureX AB

Press Releases: 2cureX AB

Quotes and Performance

Course Extremes

Managers and Directors: 2cureX AB

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-5.81%
1 week	+8.92%
Current month	+1.18%
1 month	+0.64%
3 months	+57.32%
6 months	+142.27%
Current year	+265.76%

1 week	1.65	2.4
1 month	1.64	2.4
Current year	0.52	3.27
1 year	0.51	4.4
3 years	0.2	5.52
5 years	0.2	19.4
10 years	0.2	31.5

Manager	Title	Age	Since
Grith Hagel COO	Chief Operating Officer	67	01/01/2006
Ole Thastrup CEO	Chief Executive Officer	73	-
Kenneth Graabek Johansen CEO	Chief Executive Officer	50	29/12/2023

Director	Title	Age	Since
Ole Thastrup CHM	Chairman	73	16/12/2024
Grith Hagel BRD	Director/Board Member	67	01/01/2006
Tonni Bülow-Nielsen CHM	Chairman	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
2CUREX AB	-5.81%	+8.92%	-37.95%	-57.18%	6.63M
VERACYTE, INC.	+1.65%	+5.48%	+101.09%	+110.38%	4.24B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-0.58%	+0.81%	+64.39%	+150.14%	2.78B
BGI GENOMICS CO., LTD.	-1.59%	+4.65%	-24.50%	-39.73%	2.07B
IOVANCE BIOTHERAPEUTICS, INC.	+10.84%	+16.23%	+140.00%	-44.98%	1.81B
CAREDX, INC.	+0.20%	+7.74%	+32.19%	+217.89%	1.29B
SEEGENE, INC.	-0.18%	-5.75%	-19.85%	+24.65%	813M
MARAVAI LIFESCIENCES HOLDINGS, INC.	+2.38%	+7.29%	+154.74%	-58.88%	774M
CURIOX BIOSYSTEMS CO., LTD	-14.23%	-34.88%	+22.85%	-	550M
HANGZHOU ALLTEST BIOTECH CO., LTD.	+0.25%	-6.70%	-31.58%	-16.73%	500M
Average	-0.74%	-0.59%	+40.14%	+31.73%	1.48B
Weighted average by Cap.	+0.96%	+2.20%	+64.18%	+67.82%

	2022	2023
Net sales	3.37M 347K 304K 281K 263K 492K 32.83M 500K 1.3M 16.11M 1.3M 1.27M 55.99M	2.95M 303K 266K 245K 230K 430K 28.72M 438K 1.14M 14.09M 1.14M 1.11M 48.98M
Net income	-29.77M -3.06M -2.69M -2.48M -2.32M -4.35M -290M -4.42M -11.52M -142M -11.5M -11.25M -495M	-32.52M -3.35M -2.94M -2.71M -2.54M -4.75M -317M -4.83M -12.59M -155M -12.56M -12.29M -540M
Net Debt	-44.89M -4.62M -4.06M -3.74M -3.5M -6.56M -438M -6.67M -17.38M -215M -17.34M -16.97M -746M	-13.4M -1.38M -1.21M -1.12M -1.04M -1.96M -131M -1.99M -5.19M -64.09M -5.18M -5.07M -223M